Chloroquine
Lung Cancer, Nonsmall Cell
State Key Laboratory of Respiratory DiseaseSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Lung Cancer, Nonsmall Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SLC391 SignalChem Lifesciences Corporation | Phase 1/2 | CCC |
Saf-189S Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1/2 | CCC |
QING HAU SAU State Key Laboratory of Respiratory Disease | Phase 1/2 | CCC |
Artesunate State Key Laboratory of Respiratory Disease | Phase 1/2 | CCC |
irx4204 Io Therapeutics | Phase 1 | CC |
Luveltamab Tazevibulin Sutro Biopharma, Inc. | Phase 2 | D |
Same molecule, other indications
Chloroquine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →